Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Mutat Res. 2011 Feb 15;708(1-2):59–68. doi: 10.1016/j.mrfmmm.2011.02.001

Fig. 2.

Fig. 2

Mili is required for concomitant reduction of p300 protein and increase of specific HAT activity of p300 in response to cisplatin treatment. (A) Mili-WT and KO MEFs were treated with cisplatin for 1 h, and further cultured in drug-free medium for the indicated time periods. p300 was detected using Western blotting. (B) Quantitative analysis of p300 from the blot in (A), normalized to Tubulin. (C) Mili-WT and KO MEFs were treated with cisplatin for 1 h, washed and further cultured for another 2 h. p300 was immunoprecipitated from equal amount of whole cell extract, and assayed for HAT activity, which is expressed as the OD values. Results are the mean of three independent experiments. Bars represent SD. *: p < 0.05 compared with its corresponding control. After the HAT assay, the p300 immunoprecipitates were subjected to Western blot analysis to evaluate the p300 protein levels. (C), Specific activity of p300 HAT normalized to p300 protein level (Bars: SD, n=3). **: p < 0.01 compared with their corresponding control.